using mrd to analyze the benefit of autologous sct in patients with myeloma
Published 2 years ago • 74 plays • Length 3:47Download video MP4
Download video MP3
Similar videos
-
2:55
using mrd to guide treatment decisions during sct in multiple myeloma
-
4:24
using mrd to drive maintenance therapy decisions in patients with myeloma after autosct
-
2:09
using mrd to understand the response to autosct in patients with multiple myeloma
-
0:41
mechanism of action of the tri-specific t-cell activating construct hpn217 in r/r multiple myeloma
-
2:41
the impact of sustained undetectable mrd on survival in patients with myeloma treated with ide-cel
-
11:47
petscan results. warning...not what we hoped for.
-
12:50
introduction to epigenetics - learn.omicslogic.com
-
1:47
قصة شفاء جديدة من سرطان الميلوما مع المتعافي || عبد العزيز
-
1:36
the importance of mrd as a prognostic tool in multiple myeloma
-
1:49
circulating tumor dna as a biomarker in multiple myeloma: pitfalls and future outlooks
-
0:52
mrd for multiple myeloma: is it ready for prime-time?
-
1:38
using mrd to guide therapy in multiple myeloma
-
1:09
using mrd and pet/ct to assess responses post-asct in myeloma
-
1:15
using mrd to guide treatment decisions in myeloma
-
1:04
the value of mrd in transplant-ineligible patients with multiple myeloma
-
3:24
multimodal prediction of survival in myeloma: combining mrd testing with maldi-tof ms & imaging
-
1:02
circulating plasma cell levels as a prognostic biomarker in myeloma
-
2:39
a look into the future of multiple myeloma treatment: t-cell redirecting therapies vs autohsct
-
1:33
circulating tumor cells in multiple myeloma
-
4:42
predicting mrd outcomes in myeloma using machine learning
-
1:20
mrd in myeloma
-
3:17
pet/ct with bone marrow techniques as a measure of mrd in mm patients